常用生物标记物在脓毒症中的应用现状及展望

被引：9

作者：

艾红梅

王昌富

机构：

[1] 湖北省荆州市中心医院检验医学部

来源：

实用医学杂志 | 2012年 / 28卷 / 04期

关键词：

脓毒症; 生物标记; PCT; 患者; 感染; 标记物; 降钙素原; 应用现状;

D O I：

暂无

中图分类号：

R459.7 [急症、急救处理];

学科分类号：

100218 ;

摘要：

<正>全世界每年因脓毒症而死的人数是惊人的,且其发生率呈逐年递增,但脓毒症的疗效却没有得到明显提高[1]。脓毒症的发病机制复杂,仅通过患者症状和体征来进行诊断和分层是极其困难的,但脓毒症的早期诊断和分层对于及时或特异地给予治疗是十分重要的[2]。1脓毒症的定义及所面临的困扰

引用

页码：662 / 663

页数：2

共 7 条

[1]

Biomarkers in the Critically Ill Patient: Procalcitonin[J] . Konrad Reinhart,Michael Meisner.Critical Care Clinics . 2011 (2)

[2] Is C-reactive protein a good prognostic marker in septic patients? [J].

Silvestre, Joana ;

Povoa, P. ;

Coelho, L. ;

Almeida, E. ;

Moreira, P. ;

Fernandes, A. ;

Mealha, R. ;

Sabino, H. .

INTENSIVE CARE MEDICINE, 2009, 35 (05) :909-913

[3]

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008[J] . R Phillip Dellinger,Mitchell M. Levy,Jean M. Carlet,Julian Bion,Margaret M. Parker,Roman Jaeschke,Konrad Reinhart,Derek C. Angus,Christian Brun-Buisson,Richard Beale,Thierry Calandra,Jean-Francois Dhainaut,Herwig Gerlach,Maurene Harvey,John J. Marini,John Marshall,Marco Ranieri,Graham Ramsay,Jonathan Sevransky,B Taylor Thompson,Sean Townsend,Jeffrey S. Vender,Janice L. Zimmerman,Jean-L

[4] The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis [J].

Schmit, X. ;

Vincent, J. L. .

INFECTION, 2008, 36 (03) :213-219

[5] Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children [J].

Rey, Corsino ;

Los Arcos, Marta ;

Concha, Andres ;

Medina, Alberto ;

Prieto, Soledad ;

Martinez, Pablo ;

Prieto, Belen .

INTENSIVE CARE MEDICINE, 2007, 33 (03) :477-484

[6]

Procalcitonin and other biomarkers toimprove assessment and antibioticstewardship in infections-hope for hype .2 Schuetz P,Christ-Crain M,Muller B. Swiss Med Wkly . 2009

[7]

Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target .2 KL Becker,R Snider,ES Nyles. Br J Pharmacol . 2010

← 1 →